Hikma launches Benztropine Mesylate Injection, USP

London, 24 March 2022 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it launched Benztropine Mesylate Injection, USP through its US affiliate, Hikma Pharmaceuticals USA Inc. The company has launched 2mg/2mL dose in vial format. Hikma also markets ampoules of this product and this launch broadens the choice of medicines available to hospitals.

Press Release Product 24 March 2022

text 1

Benztropine Mesylate Injection, USP is indicated as an adjunct in the therapy of all forms of parkinsonism.

According to IQVIA, US sales of Benztropine Mesylate Injection, USP, 2mg/2mL, were approximately $5 million in the 12 months ending December 2021.

Hikma is the second largest US supplier of generic injectable medicines by volume, with a growing portfolio of over 120 products. Today one in every six injectable generic medicines used in US hospitals is a Hikma product.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.